BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 6603573)

  • 1. The active site of human C4a anaphylatoxin.
    Hugli TE; Kawahara MS; Unson CG; Molinar-Rode R; Erickson BW
    Mol Immunol; 1983 Jun; 20(6):637-45. PubMed ID: 6603573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The active site of C3a anaphylatoxin.
    Caporale LH; Tippett PS; Erickson BW; Hugli TE
    J Biol Chem; 1980 Nov; 255(22):10758-63. PubMed ID: 6968751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic peptides with the biological activities and specificity of human C3a anaphylatoxin.
    Hugli TE; Erickson BW
    Proc Natl Acad Sci U S A; 1977 May; 74(5):1826-30. PubMed ID: 266705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active site of C3a anaphylatoxin: contributions of the lipophilic and orienting residues.
    Unson CG; Erickson BW; Hugli TE
    Biochemistry; 1984 Feb; 23(4):585-9. PubMed ID: 6608957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C4a: the third anaphylatoxin of the human complement system.
    Gorski JP; Hugli TE; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1979 Oct; 76(10):5299-302. PubMed ID: 291947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of casoxin C, an ileum-contracting peptide derived from bovine kappa-casein, as an agonist for C3a receptors.
    Takahashi M; Moriguchi S; Suganuma H; Shiota A; Tani F; Usui H; Kurahashi K; Sasaki R; Yoshikawa M
    Peptides; 1997; 18(3):329-36. PubMed ID: 9145417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study on biological activities of various anaphylatoxins (C4a, C3a, C5a). Investigations on their ability to induce platelet secretion.
    Meuer S; Hugli TE; Andreatta RH; Hadding U; Bitter-Suermann D
    Inflammation; 1981 Dec; 5(4):263-73. PubMed ID: 6976935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anaphylatoxin-induced histamine release with human leukocytes: studies of C3a leukocyte binding and histamine release.
    Glovsky MM; Hugli TE; Ishizaka T; Lichtenstein LM; Erickson BW
    J Clin Invest; 1979 Sep; 64(3):804-11. PubMed ID: 89118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of classical anaphylatoxin as the des-Arg form of the C5a molecule: evidence of a modulator role for the oligosaccharide unit in human des-Arg74-C5a.
    Gerard C; Hugli TE
    Proc Natl Acad Sci U S A; 1981 Mar; 78(3):1833-7. PubMed ID: 6940191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A recombinant hybrid anaphylatoxin with dual C3a/C5a activity.
    Bautsch W; Kretzschmar T; Stühmer T; Kola A; Emde M; Köhl J; Klos A; Bitter-Suermann D
    Biochem J; 1992 Nov; 288 ( Pt 1)(Pt 1):261-6. PubMed ID: 1445269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure and function of the anaphylatoxins.
    Hugli TE
    Springer Semin Immunopathol; 1984; 7(2-3):193-219. PubMed ID: 6387982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contraction of guinea pig lung by synthetic oligopeptides related to human C3a.
    Huey R; Erickson BW; Bloor CM; Hugli TE
    Immunopharmacology; 1984 Aug; 8(1):37-45. PubMed ID: 6333413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaphylatoxin-induced neutrophil chemotaxis and aggregation. Limited aggregation and specific desensitization induced by human C3a and synthetic C3a octapeptides.
    Nagata S; Glovsky MM; Kunkel SL
    Int Arch Allergy Appl Immunol; 1987; 82(1):4-9. PubMed ID: 3492446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purification and partial characterization of human and porcine C3a anaphylatoxin.
    Hugli TE; Vallota EH; Müller-Eberhard HJ
    J Biol Chem; 1975 Feb; 250(4):1472-8. PubMed ID: 803505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformational analysis of COOH-terminal segments of human C3a. Evidence of ordered conformation in an active 21-residue peptide.
    Lu ZX; Fok KF; Erickson BW; Hugli TE
    J Biol Chem; 1984 Jun; 259(12):7367-70. PubMed ID: 6610676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The C terminus of the anaphylatoxin C3a generated upon complement activation represents a neoantigenic determinant with diagnostic potential.
    Burger R; Zilow G; Bader A; Friedlein A; Naser W
    J Immunol; 1988 Jul; 141(2):553-8. PubMed ID: 2454995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the ileum-contracting mechanisms and identification as a complement C3a receptor agonist of oryzatensin, a bioactive peptide derived from rice albumin.
    Takahashi M; Moriguchi S; Ikeno M; Kono S; Ohata K; Usui H; Kurahashi K; Sasaki R; Yoshikawa M
    Peptides; 1996; 17(1):5-12. PubMed ID: 8822503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic C3a analogs as specific inhibitors of C3a activity.
    Meuer S; Hadding U; Andreatta R; Bitter-Suermann D
    Immunopharmacology; 1981 Sep; 3(3):275-80. PubMed ID: 6975766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Atopic dermatitis. II. The status of complement proteins and the pathogenetic role of anaphylatoxins C4a, C3a and C5a].
    Sergeev IuV; Reznikov IuP; Lobanova EV; Pimenova NS
    Vestn Dermatol Venerol; 1989; (4):4-7. PubMed ID: 2788339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete primary structure of human C4a anaphylatoxin.
    Moon KE; Gorski JP; Hugli TE
    J Biol Chem; 1981 Aug; 256(16):8685-92. PubMed ID: 6167582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.